SCHEDULE: Federated Hermes Discloses 11.63% Stake in Arcturus Therapeutics
Beneficial Ownership Report (Schedule 13G)
Federated Hermes, Inc. and related entities have filed an amended Schedule 13G, reporting beneficial ownership of 11.63% of Arcturus Therapeutics Holdings Inc. common stock.
Summary
- Federated Hermes, Inc., along with the Voting Shares Irrevocable Trust and its trustees (Thomas R. Donahue, Ann C. Donahue, and J. Christopher Donahue), reported beneficial ownership of 3,303,640 shares of Arcturus Therapeutics Holdings Inc. common stock.
- This ownership represents 11.63% of the class of securities.
- Federated Hermes, Inc. and the Voting Shares Irrevocable Trust hold sole voting and dispositive power over these 3,303,640 shares.
- Thomas R. Donahue, Ann C. Donahue, and J. Christopher Donahue hold shared voting and dispositive power over the same 3,303,640 shares.
- The reporting persons explicitly disclaim beneficial ownership of these securities, stating that the report should not be construed as an admission of such ownership, as the shares are held by managed funds.
Sentiment
Score: 5
Explanation: This is a routine regulatory filing disclosing beneficial ownership, which is neutral in sentiment. It does not contain performance data or strategic updates.
Future Outlook
NA
Management Comments
- In accordance with Rule 13d-4 under the Exchange Act, Federated Hermes, Inc.; the Voting Shares Irrevocable Trust; Thomas R. Donahue; Ann C. Donahue; and J. Christopher Donahue declare that this report should not be construed as an admission that any of them is the beneficial owner of the securities held by any of the Managed Funds, and each of Federated Hermes, Inc.; the Voting Shares Irrevocable Trust; Thomas R. Donahue; Ann C. Donahue; and J. Christopher Donahue expressly disclaim beneficial ownership of such securities.
Industry Context
Schedule 13G filings are routine disclosures by institutional investors, indicating passive beneficial ownership of 5% or more of a company's outstanding shares. This filing updates the market on Federated Hermes' significant, albeit passive, stake in Arcturus Therapeutics, a common practice for large asset managers holding positions across various public companies.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Ownership Structure Disclosure | Federated Hermes, Inc. is identified as a parent holding company, with its voting stock held by the Voting Shares Irrevocable Trust, whose trustees are Thomas R. Donahue, Ann C. Donahue, and J. Christopher Donahue. This clarifies the control structure behind the beneficial ownership for reporting purposes. | NA | Provides transparency regarding the ultimate control persons associated with Federated Hermes' investment decisions, without directly altering Arcturus Therapeutics' corporate governance. |
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holder's stake, which can influence market perception and liquidity.
- Management: Awareness of a large, passive institutional investor on the shareholder register.
Key Dates
| Date | Description |
|---|---|
| 12/31/2025 | Date of event requiring filing of this statement |
| 01/08/2026 | Filing date of Schedule 13G Amendment No. 3 |
Keywords
Arcturus Therapeutics Holdings Inc., Federated Hermes Inc., Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Investment Adviser, Holding Company, ARCT
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.